GOVERNMENT COUNSEL, LLC for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 4348-Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act relating to 180-day exclusivity reform.
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Budget/Appropriations BUD
Monitor issues relating to negotiating Medicare prescription drug prices in the Inflation Reduction Act (H.R. 5376).
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.